These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 36959286)

  • 1. Mechanism and treatments of antipsychotic-induced weight gain.
    Ye W; Xing J; Yu Z; Hu X; Zhao Y
    Int J Obes (Lond); 2023 Jun; 47(6):423-433. PubMed ID: 36959286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
    Remington G
    Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
    Hasnain M; Fredrickson SK; Vieweg WV; Pandurangi AK
    Curr Diab Rep; 2010 Jun; 10(3):209-16. PubMed ID: 20425584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine metabolic side effects: a weight gain issue?
    Carulli L; Mazzi F; Rondinella S; Bertolotti M
    Intern Emerg Med; 2008 Sep; 3(3):237-40. PubMed ID: 18369533
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and tolerance of antipsychotic agents: what are the current issues?].
    Canceil O
    Encephale; 2006 Oct; 32(5 Pt 4):S927-8. PubMed ID: 17119510
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.
    Ebdrup BH; Knop FK; Ishøy PL; Rostrup E; Fagerlund B; Lublin H; Glenthøj B
    BMC Med; 2012 Aug; 10():92. PubMed ID: 22891821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical Health and Drug Safety in Individuals with Schizophrenia.
    Pringsheim T; Kelly M; Urness D; Teehan M; Ismail Z; Gardner D
    Can J Psychiatry; 2017 Sep; 62(9):673-683. PubMed ID: 28718324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and antipsychotic treatment response.
    Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Brazilian Consensus on second-generation antipsychotics and metabolic disorders].
    Elkis H; Gama C; Suplicy H; Tambascia M; Bressan R; Lyra R; Cavalcante S; Minicucci W
    Braz J Psychiatry; 2008 Mar; 30(1):77-85. PubMed ID: 18373022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics.
    Jesus C; Jesus I; Agius M
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S489-91. PubMed ID: 26417824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial.
    Chan M; Qin Z; Man SC; Lam M; Lai WH; Ng RMK; Lee CK; Wong TL; Lee EHM; Wong HK; Feng Y; Liu L; Han F; Chen EYH; Zhang ZJ
    Psychiatry Clin Neurosci; 2022 Mar; 76(3):77-85. PubMed ID: 34931749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness criterion: balancing efficacy against the risks of weight gain.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():12-7. PubMed ID: 17956151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem.
    Andrade C
    J Clin Psychiatry; 2016 Jul; 77(7):e844-7. PubMed ID: 27464317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
    Mennella C; Dickstein DP
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):106-107. PubMed ID: 27548055
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
    Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
    Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
    Attux C; Quintana MI; Chaves AC
    Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
    Henderson DC; Doraiswamy PM
    J Clin Psychiatry; 2008; 69 Suppl 1():32-44. PubMed ID: 18484806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.
    Henderson DC
    J Clin Psychiatry; 2008 Feb; 69(2):e04. PubMed ID: 18363448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.
    Libowitz MR; Nurmi EL
    Front Psychiatry; 2021; 12():623681. PubMed ID: 33776816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.